Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
Rhea-AI Summary
Propanc Biopharma (Nasdaq: PPCB) reported new preclinical and early translational results for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC). In orthotopic and patient-derived xenograft models of advanced PDAC, 3x-weekly intravenous PRP achieved >90% mean tumor growth inhibition versus vehicle controls, marked metastatic burden reductions in liver and peritoneum, and a median overall survival extension of more than 2.5-fold in treated animals.
According to Propanc, PRP also remodeled the tumor microenvironment and enhanced sensitivity of chemo‑resistant PDAC cells to gemcitabine/nab‑paclitaxel. The company plans to accelerate a Phase 1b first‑in‑human study in approximately 30–40 advanced solid‑tumor patients, targeting clinical trial application submission in Australia in the coming months. PRP has FDA Orphan Drug Designation for pancreatic cancer, with GMP manufacturing targeted for late 2026 and a memorandum of understanding with Avance Clinical to support trial execution.
Positive
- >90% tumor growth inhibition in advanced PDAC preclinical models
- 2.5-fold median survival extension in PRP-treated PDAC animal models
- Preclinical data indicate reduced metastatic burden in liver and peritoneum
- PRP received FDA Orphan Drug Designation for pancreatic cancer
- Planned Phase 1b first-in-human trial in 30–40 advanced solid-tumor patients
- GMP manufacturing for PRP targeted for late 2026
Negative
- None.
Market Reaction – PPCB
Following this news, PPCB has gained 2.86%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 10 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $1.21. Trading volume is very high at 3.7x the average, suggesting strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | Research publication | Positive | +0.0% | Peer-reviewed publication evaluated recombinant proenzymes for biotechnology and therapeutic applications. |
| Jul 07 | Clinical partnership | Positive | -3.2% | Non-binding Avance Clinical MOU supported planned Phase 1b first-in-human trial preparation. |
| Jul 02 | Share repurchase | Positive | +22.9% | Company announced a $5.0 million repurchase program with an initial $500,000 tranche. |
| Jun 16 | Manufacturing update | Positive | -10.2% | Manufacturing planning supported a Phase 1b study in 30–40 advanced solid-tumor patients. |
| Jun 11 | Share repurchase | Positive | +80.0% | Company authorized a $5.0 million common-stock repurchase program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent PPCB news reactions were mixed, with strong gains after buyback announcements but declines following the Avance MOU and manufacturing update.
Key Terms
pancreatic ductal adenocarcinoma medical
patient-derived xenograft medical
tumor microenvironment medical
epithelial-mesenchymal transition medical
pharmacokinetics medical
gmp regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accelerates Phase 1b First-in-Human Trial Timeline
MELBOURNE, Australia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced compelling new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and treatment-resistant solid tumors.
In orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, 3 times weekly intravenous PRP achieved:
- Greater than
90% mean tumor growth inhibition versus vehicle controls (p < 0.001) - Marked reduction in metastatic burden in liver and peritoneum
- Significant remodeling of the tumor microenvironment, including decreased cancer-associated fibroblast activity, reduced fibrosis, and suppression of epithelial-mesenchymal transition (EMT) markers
- Enhanced sensitivity of chemo-resistant PDAC cells to standard-of-care gemcitabine/nab-paclitaxel, allowing lower chemotherapy doses while improving efficacy
- Median overall survival extension of more than 2.5-fold in treated animals compared with controls
These results are built on previously reported >
“Pancreatic cancer remains one of oncology’s greatest challenges, with five-year survival rates still near
PRP is a proprietary fixed-ratio combination of the pancreatic proenzymes, trypsinogen and chymotrypsinogen, administered by once – weekly intravenous injection. The U.S. Food and Drug Administration previously granted Orphan Drug Designation to PRP for the treatment of pancreatic cancer.
The Company has advanced manufacturing (GMP production targeted for late 2026), pharmacokinetics assay validation, and clinical partnerships, including a memorandum of understanding with Avance Clinical, to support efficient execution of the planned Phase 1b study in approximately 30 – 40 patients with advanced solid tumors.
The global pancreatic cancer treatment market is projected to grow substantially in the coming years amid rising incidence and demand for therapies that address metastasis and resistance. Propanc believes PRP’s unique mechanism positions it as a potential complementary or alternative approach that could improve outcomes while offering a more favorable tolerability profile than many existing regimens.
Further details of the new studies are expected to be presented at an upcoming scientific meeting. The Company remains focused on initiating the Phase 1b trial as rapidly as possible and generating the clinical data needed to advance PRP into proof-of-concept studies in PDAC and other high-unmet-need solid tumors.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.
More information: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
Investor Contact:
